Everaldo Hertz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Everaldo Hertz has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Fernanda Barbisan
Universidade Federal de Santa Maria
2 shared publications - Ivana Beatrice Mânica da Cruz
Universidade Federal de Santa Maria
2 shared publications - Ivo Emilio da Cruz Jung
Centro de Ensino, Pesquisa e Desenvolvimento Tecnológico GERONTEC, Fundação Universidade Aberta da Terceira Idade, FUnATI, Manaus 69029-040, AM, Brazil
2 shared publications - Bárbara Osmarin Turra
Universidade Federal de Santa Maria (UFSM). Santa Maria (RS), Brasil
1 shared publication - Bárbara Osmarin Turra
Research, Teaching and Technological Development Center, Fundação Universidade Aberta da Terceira Idade, Manaus 69029-040, Brazil
1 shared publication Carlos Fernando Antunes Gonçalves
1 shared publication
Latest Publications
- Open Access
- 6 March 2025
- Published by Revista Brasileira De Cancerologia (RBC) in Revista Brasileira de Cancerologia
- Vol. 71 (2)
Paclitaxel Modulates the Proliferation and Differentiation of THP-1 Cells Exposed to Inactivated SARS-CoV-2 Virus
Introduction: Cancer patients were considered a high-risk group for COVID-19. Studies indicate that certain types of cancer, as breast cancer, may exhibit distinct immunological responses. Evidence suggests that paclitaxel (PTX), a chemotherapeutic agent widely used in the treatment of breast cancer, has immunomodulatory properties, which could contribute to attenuate the inflammatory response caused by the SARS-CoV-2 virus. Objective: To evaluate the effect of PTX on the THP-1 immune cell line activated by non-viral immunogenic agent 12-O-tetradecanoylphorbol-13-acetate (TPA) and by inactivated SARS-CoV-2 virus derived from the CoronaVac vaccine (CVac). Method: An in vitro study was conducted, initially determining the minimum concentration of CVac required to activate THP-1 cells. Subsequently, the cytotoxic action of PTX on THP-1 cells was investigated, followed by the analysis of the immunomodulatory effect of PTX through the evaluation of cell proliferation rate, cytomorphological differentiation, levels of nitric oxide, superoxide anion, and gene expression of the cytokines tumor necrosis factor-alpha and interleukin 10. Results: In 24-hour, 5% CVac activated THP-1 cells, triggering more significant proliferation and cell differentiation, compared to the control. No cytotoxic effects of PTX were observed. PTX reduced the cell differentiation rate and superoxide levels when co-exposed with TPA or CVac, but did not modulate cytokine gene expression. Conclusion: The data indicate that PTX could modulate in vitro immune activation in response to viral and non-viral immunogenic agents, suggesting that it could attenuate the inflammatory response to antigens, including SARS-CoV-2.
- 6 March 2025
- Published by Revista Brasileira De Cancerologia (RBC) in Revista Brasileira de Cancerologia
- Vol. 71 (2)
Open AccessPaclitaxel Modulates the Proliferation and Differentiation of THP-1 Cells Exposed to Inactivated SARS-CoV-2 Virus
Introduction: Cancer patients were considered a high-risk group for COVID-19. Studies indicate that certain types of cancer, as breast cancer, may exhibit distinct immunological responses. Evidence suggests that paclitaxel (PTX), a chemotherapeutic agent widely used in the treatment of breast cancer, has immunomodulatory properties, which could contribute to attenuate the inflammatory response caused by the SARS-CoV-2 virus. Objective: To evaluate the effect of PTX on the THP-1 immune cell line activated by non-viral immunogenic agent 12-O-tetradecanoylphorbol-13-acetate (TPA) and by inactivated SARS-CoV-2 virus derived from the CoronaVac vaccine (CVac). Method: An in vitro study was conducted, initially determining the minimum concentration of CVac required to activate THP-1 cells. Subsequently, the cytotoxic action of PTX on THP-1 cells was investigated, followed by the analysis of the immunomodulatory effect of PTX through the evaluation of cell proliferation rate, cytomorphological differentiation, levels of nitric oxide, superoxide anion, and gene expression of the cytokines tumor necrosis factor-alpha and interleukin 10. Results: In 24-hour, 5% CVac activated THP-1 cells, triggering more significant proliferation and cell differentiation, compared to the control. No cytotoxic effects of PTX were observed. PTX reduced the cell differentiation rate and superoxide levels when co-exposed with TPA or CVac, but did not modulate cytokine gene expression. Conclusion: The data indicate that PTX could modulate in vitro immune activation in response to viral and non-viral immunogenic agents, suggesting that it could attenuate the inflammatory response to antigens, including SARS-CoV-2.
- Open Access
- 1 December 2023
- Published by Brazilian Journals in Contribuciones A Las Ciencias Sociales
- Vol. 16 (12) , 32178-32197
Does breast Cancer have a lower risk of mortality from Severe Acute Respiratory Syndrome compared to other types of Cancer? Evidence from Brazil, a heterogeneous population
To investigate the prevalence of hospitalizations and deaths related to severe acute respiratory syndrome in Brazilian women diagnosed with breast cancer. A 12-month retrospective study was performed using data from hospitalized women patients resulting from SARS-CoV-2 infection from a national database of acute respiratory lower disease notification forms (ARDL) between January 1 and December 2021. Data from non-pregnant and non-puerperium women> 18 years and with laboratory, COVID-19 diagnosis were selected and analyzed from 1048575 databank patients and categorized into three groups: without cancer diagnosis (WC), with breast cancer (BC), and with a diagnosis of other types of cancer (OC). OC was also sub-categorized in eight types of diagnosed cancer. Mortality and other clinical complications during the hospitalized period were compared between groups by analysis of variance followed by the post hoc Bonferroni test and the chi-square test. The influence of the following covariates was determined by multivariate logistic regression analysis: age, education, ethnicity, previous immunization to COVID-19, and presence of risk comorbidities. Brazilian BC had a lower risk of mortality from ARDL-COVID than those diagnosed OC patients. However, both groups presented a higher mortality risk than WC patients. Conclusions: These results are like some previous studies suggesting that BC lower risk could be a universal phenomenon independent of ethnicity and the presence of other risk comorbidities for COVID-19.
- 1 December 2023
- Published by Brazilian Journals in Contribuciones A Las Ciencias Sociales
- Vol. 16 (12) , 32178-32197
Open AccessDoes breast Cancer have a lower risk of mortality from Severe Acute Respiratory Syndrome compared to other types of Cancer? Evidence from Brazil, a heterogeneous population
To investigate the prevalence of hospitalizations and deaths related to severe acute respiratory syndrome in Brazilian women diagnosed with breast cancer. A 12-month retrospective study was performed using data from hospitalized women patients resulting from SARS-CoV-2 infection from a national database of acute respiratory lower disease notification forms (ARDL) between January 1 and December 2021. Data from non-pregnant and non-puerperium women> 18 years and with laboratory, COVID-19 diagnosis were selected and analyzed from 1048575 databank patients and categorized into three groups: without cancer diagnosis (WC), with breast cancer (BC), and with a diagnosis of other types of cancer (OC). OC was also sub-categorized in eight types of diagnosed cancer. Mortality and other clinical complications during the hospitalized period were compared between groups by analysis of variance followed by the post hoc Bonferroni test and the chi-square test. The influence of the following covariates was determined by multivariate logistic regression analysis: age, education, ethnicity, previous immunization to COVID-19, and presence of risk comorbidities. Brazilian BC had a lower risk of mortality from ARDL-COVID than those diagnosed OC patients. However, both groups presented a higher mortality risk than WC patients. Conclusions: These results are like some previous studies suggesting that BC lower risk could be a universal phenomenon independent of ethnicity and the presence of other risk comorbidities for COVID-19.